<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-325
Date of Submission: 2024-12-02

This report was submitted by a Other Healthcare Professional from Sawyer, Esparza and Yu Medical Center concerning patient ANON-PX-6226. The subject is a 62-year-old male with a significant medical history including chronic kidney disease, anxiety, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen administered via the Subcutaneous route at a dosage of 279mg, initiated on 2024-09-27 for Pain and inflammation and discontinued on 2024-11-02; Atorvastatin administered via the Intramuscular route at a dosage of 397mg, initiated on 2024-09-27 for Hypercholesterolemia and discontinued on 2024-11-02.

On approximately 2024-10-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Headache. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed church and advised our. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed her and advised particular. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2024-325
report_date: '2024-12-02'
patient_details:
  patient_id: ANON-PX-6226
  gender: Male
  relevant_history:
  - chronic kidney disease
  - anxiety
  - seasonal allergies
  age_at_reaction: 62
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 279mg
  route_of_administration: Subcutaneous
  start_date: '2024-09-27'
  indication_for_use: Pain and inflammation
  end_date: '2024-11-02'
- drug_name: Atorvastatin
  dosage: 397mg
  route_of_administration: Intramuscular
  start_date: '2024-09-27'
  indication_for_use: Hypercholesterolemia
  end_date: '2024-11-02'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2024-10-04'
  severity: Severe
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed church and advised our.
- symptom_name: Headache
  onset_date: '2024-10-04'
  severity: Severe
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed her and advised particular.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 4
reporting_facility: Sawyer, Esparza and Yu Medical Center
reporter_type: Other Healthcare Professional
